Biocon Shares Fall After Profit Declines In December Quarter
Business | Edited by Abhishek Vasudev | Friday January 22, 2021
On a standalone basis, Biocon's profit plunged 72 per cent annually to Rs 33 crore from Rs 121 crore during the same period last year.
Biocon To Buy 26% Stake In Hinduja Renewables Two
Business | Edited by Peter Noronha | Tuesday November 24, 2020
"The cost of the acquisition is Rs 5,91,61,730 for the acquisition of 26 per cent stake on a fully diluted basis in one or more tranches," the Bangalore-based Biocon said in a BSE filing.
Biocon Soars Nearly 10% On Receiving Nod For Covid-19 Drug
Business | Edited by Peter Noronha | Monday July 13, 2020
Biocon Share: Biocon received approval from the Drugs Controller General of India to market its novel biologic drug Itolizumab for treating patients having Covid-19 complications.
Biocon Shares Fall After Profit Declines In December Quarter
Business | Edited by Abhishek Vasudev | Friday January 22, 2021
On a standalone basis, Biocon's profit plunged 72 per cent annually to Rs 33 crore from Rs 121 crore during the same period last year.
Biocon To Buy 26% Stake In Hinduja Renewables Two
Business | Edited by Peter Noronha | Tuesday November 24, 2020
"The cost of the acquisition is Rs 5,91,61,730 for the acquisition of 26 per cent stake on a fully diluted basis in one or more tranches," the Bangalore-based Biocon said in a BSE filing.
Biocon Soars Nearly 10% On Receiving Nod For Covid-19 Drug
Business | Edited by Peter Noronha | Monday July 13, 2020
Biocon Share: Biocon received approval from the Drugs Controller General of India to market its novel biologic drug Itolizumab for treating patients having Covid-19 complications.
................................ Advertisement ................................
................................ Advertisement ................................
